Financial Stability

In the past, pharmaceutical and biotechnology companies have pursued outsourcing as a tactical necessity, which was driven by capacity needs or specific niche capability requirements. The main criteria to select a CMO were timelines, cost, its technical ability and its manufacturing and quality systems. Financial stability was considered to be of minor importance. These days outsourcing to a CMO becomes more and more important for many pharmaceutical and biotechnology companies and is increasing the reliance on CMOs for the production of their biopharmaceuticals. Pharmaceutical and biotechnology companies therefore are looking to form long term strategic partnerships with CMOs to guarantee reliable delivery of material for both the clinic and market, which is only possible if the CMO is financially stable. 

SynCo as a CMO has contracts for commercial supply that extend into the next decade, giving a considerable security of income, and enabling SynCo to form long term strategic partnerships for early and late stage manufacture of biopharmaceuticals. This financial stability is not possible for organizations whose primary focus and experience is in the manufacture of early stage products. 

As a client you will benefit from this financial stability through:

• increased overall product value through a strong long term manufacturing partner
• sufficient resources for your project
• state-of-the-art equipment